Kymriah wins second FDA OK, boosting hope for Novartis' low CAR-T sales
After disappointing investors this year with sluggish sales, the prospects for Novartis’ CAR-T therapy Kymriah may be improving. The FDA has handed the pharma giant its second approval for the drug, the company said Tuesday afternoon.
The drug, which was first approved last August for patients under 25 with B-cell precursor acute lymphoblastic leukemia, is now OK’ed to treat large B-cell lymphoma. The cancer must be relapsed or refractory, and the patient must have gone through two or more lines of systemic therapy first.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
